Gilead Sciences (NASDAQ:GILD) has been assigned a $94.00 price objective by investment analysts at Maxim Group in a research note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price indicates a potential upside of 20.17% from the company’s current price.
GILD has been the subject of several other research reports. Credit Suisse Group set a $80.00 price target on Gilead Sciences and gave the stock a “hold” rating in a report on Wednesday, January 3rd. Mizuho lifted their target price on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. BMO Capital Markets decreased their target price on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a report on Friday, October 27th. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a report on Thursday, December 14th. Finally, Zacks Investment Research cut Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, January 18th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $85.58.
Shares of Gilead Sciences (NASDAQ GILD) traded down $0.15 during midday trading on Tuesday, reaching $78.22. The company’s stock had a trading volume of 4,509,893 shares, compared to its average volume of 8,610,000. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The firm has a market capitalization of $101,560.00, a P/E ratio of 8.90, a PEG ratio of -1.80 and a beta of 1.22. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $89.54.
Several institutional investors have recently made changes to their positions in the company. Capital International Investors increased its holdings in shares of Gilead Sciences by 86.6% in the 3rd quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after acquiring an additional 5,205,983 shares during the last quarter. Sanders Capital LLC increased its holdings in shares of Gilead Sciences by 102.9% in the 4th quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock valued at $757,119,000 after acquiring an additional 5,026,015 shares during the last quarter. Skandinaviska Enskilda Banken AB publ increased its holdings in shares of Gilead Sciences by 230.0% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock valued at $399,233,000 after acquiring an additional 3,434,450 shares during the last quarter. CI Global Investments Inc. increased its holdings in shares of Gilead Sciences by 5,461.1% in the 4th quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock valued at $237,675,000 after acquiring an additional 3,257,969 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Gilead Sciences by 35.0% in the 2nd quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after purchasing an additional 2,700,600 shares during the period. 75.84% of the stock is currently owned by institutional investors and hedge funds.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
